Banner Life Sciences LLC

Patheon Softgels Inc.

Banner Pharmacaps, Inc.

Patheon Signals Inc.

Aqeel A Fatmi

Tatyana Dyakonov

Sunil Agnihotri

Justin R Hughey

Jason M Vaughn

Tanesha Roberts

Saujanya L Gosangari

Nachiappan Chidambaram

Chue Yang

George Vamvakas

YinYan Zhao

Yunhua Hu

Martin Piest

Henricus Marinus Gerardus Maria Van Duijnhoven

Peijin Zhang

Mervin Williams, Jr

Shingai Majuru

EmadEldin M Hassan

Nachiapan Chidambaram

Karla E Madrigal

Tae Kyoung Kim

Dana S Toops

Derek Bush

Zhi Liu

Yang Hue Chue

Yinyan Zhao

Saujanya Gosangari

Emadeldin M Hassan

Mervin Williams

Chue Hue Yang

Described herein are oral pharmaceutical compositions suitable for chewing, sucking, or buccal dissolution comprising soft gel capsules and liquid fills, methods for making the same, and methods for treating subjects in need thereof with such capsules. In particular, oral pharmaceutical compositions comprising chewable, suckable, or dissolvable soft gel capsules with various flowable fill compositions are described.

Liquisoft capsules

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.

Fumarate ester dosage forms

Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.

Liquid dosage forms of sodium naproxen

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.

Fumarate ester pharmaceutical compositions

Described herein are pharmaceutical compositions comprising one or more fumarate esters, processes for making the same, and compositions and methods for treating multiple sclerosis subjects with the compositions. In particular, oral pharmaceutical compositions comprising fumarate esters in liquid vehicles are described. One embodiment is an oral delayed release pharmaceutical dosage form comprising a soft capsule encapsulating an immediate releasing liquid comprising one or more fumarate esters.

Fumarate esters

Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.

Abuse-deterrent opioids

Opioid abuse-deterrent controlled release formulations

Described herein are pharmaceutical compositions providing enhanced bioavailability of polyunsaturated fatty acids and methods of manufacturing the same. In particular, described herein are pharmaceutical compositions comprising soft enteric capsules that provide enhanced bioavailability of omega-3 polyunsaturated fatty acids. The oral pharmaceutical compositions described herein are useful as nutritional supplements or for the treatment of cardiovascular-related diseases, such as hyper dyslipidemia and moderate to high triglyceride levels.

Enhanced bioavailability of polyunsaturated fatty acids

Described herein are pharmaceutical compositions comprising polyunsaturated fatty acids and methods of manufacturing the same. In particular, described herein are pharmaceutical compositions comprising soft enteric capsules comprising omega-3 polyunsaturated fatty acids. The oral pharmaceutical compositions described herein are useful as nutritional supplements or for the treatment of cardiovascular-related diseases, such as hyper dyslipidemia and high triglyceride levels.

Enteric soft capsules comprising polyunsaturated fatty acids

Abuse-deterrent controlled release formulations

Described herein are controlled release oral pharmaceutical compositions for delivering active pharmaceutical ingredients to the colon and methods for making the same. In particular, an oral pharmaceutical composition comprising a soft capsule and a controlled release matrix for delivering active pharmaceutical ingredients to the colon are described.

Compositions for colonic delivery of drugs

Growing community of inventors

High Point, NC, United States of America

Aqeel A Fatmi